- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1229208-44-9] Entospletinib
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-15968 |
| Brand: | MCE |
| CAS: | 1229208-44-9 |
Overview
| MDL | MFCD28099806 |
|---|---|
| Molecular Weight | 411.46 |
| Molecular Formula | C23H21N7O |
| SMILES | C12=NC=CN1C=C(C3=CC4=C(C=C3)C=NN4)N=C2NC5=CC=C(N6CCOCC6)C=C5 |
4 Publications Citing Use of MCE
Summary
Entospletinib (GS-9973) is an orally bioavailable, selective Syk inhibitor with an IC 50 of 7.7 nM.
IC50 & Target
IC50: 7.7 nM (Syk)
In Vitro
Entospletinib (GS-9973) shows good bidirectional permeability across Caco-2 cell monolayers in vitro. In cells, Entospletinib (GS-9973) also shows excellent selectivity for Syk, and potently inhibits BCR-mediated activation and proliferation of B-cells as well as immune-complex-stimulated cytokine production in monocytes [1] . The combination of idelalisib and Entospletinib (GS-9973) synergistically inhibits CLL cell viability and further disrupts chemokine signaling [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Entospletinib (GS-9973) (1 mg/kg, p.o.) shows moderate to high bioavailability in rat and dog. In a rat collagen-induced arthritis model, Entospletinib (GS-9973) (1-10 mg/kg, p.o.) significantly inhibits ankle inflammation. Moreover, Entospletinib (GS-9973) also shows disease-modifying activity in multiple histological measurements, including inhibition of pannus formation, cartilage damage, bone resorption, and peritosteal bone formation with ED 50 ranging from 1.2 to 3.9 mg/kg [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01799889 | Gilead Sciences |
Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Diffuse Large B-cell Lymphoma|Non-FL Indolent Non-Hodgkin´s Lymphoma|Follicular Lymphoma
|
March 14, 2013 | Phase 2 |
| NCT02457598 | Gilead Sciences |
B-cell Malignancies
|
June 16, 2015 | Phase 1 |
| NCT03010358 | Alexey Danilov, MD|Gilead Sciences|Oregon Health and Science University|OHSU Knight Cancer Institute |
Anemia|B-Cell Prolymphocytic Leukemia|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Hairy Cell Leukemia|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma|Richter Syndrome
|
July 17, 2017 | Phase 1|Phase 2 |
| NCT02568683 | Gilead Sciences |
Non-Hodgkin Lymphoma
|
February 11, 2016 | Phase 1|Phase 2 |
| NCT03013998 | Beat AML, LLC |
Previously Untreated Acute Myeloid Leukemia
|
November 2016 | Phase 1|Phase 2 |
| NCT02343939 | Gilead Sciences |
Acute Myeloid Leukemia
|
July 1, 2015 | Phase 1|Phase 2 |
| NCT02521376 | Gilead Sciences |
Oncology
|
November 16, 2015 | Phase 1 |
| NCT03135028 | Gilead Sciences |
Hematologic Malignancy|Acute Myeloid Leukemia
|
May 19, 2017 | Phase 1 |
| NCT02404220 | Gilead Sciences |
Acute Lymphoblastic Leukemia
|
May 6, 2015 | Phase 1|Phase 2 |
| NCT05020665 | Kronos Bio |
Nucleophosmin 1-mutated Acute Myeloid Leukemia
|
November 30, 2021 | Phase 3 |
| NCT01796470 | Gilead Sciences |
Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Diffuse Large B-cell Lymphoma|Indolent Non-Hodgkin´s Lymphoma
|
June 20, 2013 | Phase 2 |
| NCT03225924 | The Lymphoma Academic Research Organisation |
DLBCL
|
July 26, 2017 | Phase 1|Phase 2 |
| NCT02983617 | Gilead Sciences|German CLL Study Group |
Chronic Lymphocytic Leukemia
|
April 6, 2017 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 43 mg/mL ( 104.51 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4304 mL | 12.1518 mL | 24.3037 mL |
| 5 mM | 0.4861 mL | 2.4304 mL | 4.8607 mL |
| 10 mM | 0.2430 mL | 1.2152 mL | 2.4304 mL |
-
1.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.08 mM); Clear solution
References
- [1] Currie KS, et al. Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase. J Med Chem. 2014 May 8;57(9):3856-73.
- [2] Burke RT, et al. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget. 2014 Feb 28;5(4):908-15.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.